The elfamycins are so named because they exhibit antimicrobial activity through the inhibition of protein biosynthesis via binding to the
el
ongation
fa
ctor Tu. Known elfamycins include aurodox, C
44
H
62
N
2
O
12
; kirromycin, C
43
H
60
N
2
O
12
; azdimycin, efrotomycin, C
59
H
88
N
2
O
20
; dihydromocimycin, C
43
H
62
N
2
O
12
; heneicomycin, C
44
H
62
N
2
O
11
; kirrothricin, C
44
H
64
N
2
O
10
; factumycin, C
44
H
62
N
2
O
10
; MSD A63A, L681,217, C
36
H
53
N
1
O
10
; SB22484, factor 3, C
41
H
56
N
2
O
11
; SB22484, factor 4, C
42
H
58
N
2
O
11
; phenelfamycin A, C
51
H
71
N
1
O
15
; phenelfamycin B, C
61
H
71
N
1
O
15
; phenelfamycin C, C
58
H
83
N
1
O
18
; phenelfamycin D, C
58
H
83
N
1
O
18
; phenelfamycin E, C
65
H
95
N
1
O
21
; phenelfamycin F, C
65
H
95
N
1
O
21
; unphenelfamycin, C
43
H
65
N
1
O
14
; LL‐E19020α, C
65
H
95
N
1
O
21
; LL‐E19020β, C
65
H
95
N
1
O
21
; UK‐69,753, C
58
H
86
N
2
O
18
; and
N
‐demethylefrotomycin, C
58
H
86
N
2
O
20
. These antibiotics are distinguished by low mammalian toxicity, narrow‐range antimicrobial activity, and positive effects on feed utilization and growth promotion in farm animals. Elfamycins are natural products. Aurodox and efrotomycin have been synthesized chemically. Elfamycins are slightly acidic and soluble in most polar organic solvents, and the alkali and ammonium salts are water‐soluble. Elfamycins block bacterial protein biosynthesis at the level of elongation factor Tu (EF‐Tu). Elfamycins have similar
in vitro
antimicrobial spectra and the activity against
Moraxella, Pasteurella, Yersinia, Haemophilus, Streptococcus, Corynebacterium,
and
Neisseria
appears to be common. Elfamycins, in general, enhance the growth of farm animals. Efrotomycin is being developed as a growth‐promoting agent for swine. The potential usefulness of elfamycins as growth promotors and feed‐conversion enhancers is now generally recognized. Low original fermentation yields and difficulties in yield improvements discouraged early attempts to develop aurodox and mocimycin (kirromycin) commercially. A development program for efrotomycin, however, is ongoing. Some of the newer elfamycins, such as the LL‐E19020 pair, are considerably more active growth promotors than aurodox or mocimycin, pointing toward a second generation of elfamycins.